VD-CAG AML Study: 11-Gene Prognostic Signature from Multi-Omics Profiling

15 non-M3 acute myeloid leukemia patients were profiled with RNA sequencing and proteomics to study response to VD-CAG therapy. An 11-gene prognostic signature was derived and validated using the TCGA-LAML and Beat AML cohorts. The dataset, authored by Jirui Tang, was last updated on 2026-05-19.

Use Cases

• Validate the 11-gene prognostic signature (TLN1, ARL15, etc.) in independent AML cohorts.
• Analyze molecular alterations in MAPK signaling and cell adhesion pathways post-VD-CAG treatment.
• Investigate the correlation between gene co-expression modules and composite complete remission.
• Study the proteomic changes, including the downregulation of FNDC3B, associated with treatment intervention.

Strengths

• Integrates multi-omics data from 15 patient samples, including RNA-seq and proteomics.
• Prognostic signature was validated in an external cohort (Beat AML) with a reported 3-year AUC of 0.83.
• Analysis includes results from weighted gene co-expression network analysis (WGCNA) and LASSO regression.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The sample size of 15 patients for the primary multi-omics analysis is relatively small.

Provenance

Source

figshare

Collection Method

Integrative multi-omics profiling (RNA sequencing, DIA proteomics) of bone marrow samples from a clinical study.

Freshness

Last updated 2026-05-19 04:22:46; freshness should be verified.